July 6, 2020 / 11:12 AM / a month ago

BRIEF-Regeneron Announces Start Of Regn-Cov2 Phase 3 Covid-19 Prevention Trial With National Institute Of Allergy And Infectious Diseases

July 6 (Reuters) - Regeneron Pharmaceuticals Inc:

* REGENERON ANNOUNCES START OF REGN-COV2 PHASE 3 COVID-19 PREVENTION TRIAL IN COLLABORATION WITH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID)

* REGENERON PHARMACEUTICALS INC - ANTI-VIRAL ANTIBODY COCKTAIL REGN-COV2 IS ALSO IN PHASE 2/3 TREATMENT TRIALS FOLLOWING POSITIVE PHASE 1 SAFETY REVIEW

* REGENERON PHARMACEUTICALS - PHASE 3 PREVENTION TRIAL IS BEING CONDUCTED AT APPROXIMATELY 100 SITES AND IS EXPECTED TO ENROLL 2,000 PATIENTS IN U.S.

* REGENERON - TWO PHASE 2/3 TREATMENT TRIALS IN PATIENTS PLANNED TO BE CONDUCTED AT ABOUT 150 SITES IN U.S., BRAZIL, MEXICO AND CHILE

* REGENERON PHARMA - PRELIMINARY DATA FROM 2 PHASE 2/3 TREATMENT TRIALS IN HOSPITALIZED & NON-HOSPITALIZED PATIENTS EXPECTED LATER THIS SUMMER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below